Have you or your loved ones been diagnosed with spinal cord injury?

You may be eligible to participate in a spinal cord injury clinical trial.

Have you or your loved ones been diagnosed with spinal cord injury? You may be eligible to participate in a spinal cord injury clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Spinal Cord Injury Clinical Trial
NCT01597518 | Phase 2 phase 3 | Interventional

Have you or your loved ones been diagnosed with spinal cord injury?

You may be eligible to participate in a spinal cord injury clinical trial.

Have you or your loved ones been diagnosed with spinal cord injury? You may be eligible to participate in a spinal cord injury clinical trial.

Active not recruiting

Male & Female

18 - 75

Years old

This study is looking to recruit 351 Participants

The aim of this study is to evaluate efficacy and safety of riluzole in the treatment of patients with acute SCI. The primary objective is to evaluate the superiority of riluzole, at a dose of 2 x 100 mg the first 24 hours followed by 2 x 50 mg for the following 13 days after injury, as compared to placebo, in change between 180 days and baseline in motor outcomes as measured by International Standards for Neurological Classification of Spinal Cord Injury Examination (ISNCSCI) Motor Score, in patients with acute traumatic SCI, presenting to the hospital less than 12 hours after injury. Secondary objectives are to evaluate the effects of riluzole on overall neurologic recovery, sensory recovery, functional outcomes, quality of life outcomes, health utilities, mortality, and adverse events. The working hypothesis is that the riluzole treated subjects will experience superior motor, sensory, functional, and quality of life outcomes as compared to those receiving placebo, with an acceptable safety profile.